Development and Validation of a TNF Family-Based Signature for Predicting Prognosis, Tumor Immune Characteristics, and Immunotherapy Response in Colorectal Cancer Patients

Figure 2

Establishment of the TNF family-based signature (TFS). (a) Heatmap of the mRNA expression of the eight genes in the TFS, survival status, and TFS risk scores in the high- and low-risk groups. (b) The Kaplan–Meier curves of the OS of CRC patients in the high- and low-risk groups. (c) Validation of the prognostic value of the eight-gene TFS at 1, 3, and 5 years via time-dependent ROC curve analysis in the TCGA cohort. The Kaplan–Meier survival analyses of the patients in the high- and low-risk groups with (d) early-stage CRC (stages I and II) () and (e) advanced-stage CRC (stages III and IV) ().

(a)

(b)

(c)

(d)

(e)